PDSB vs. EBS, IOBT, RNAC, ANIX, CLRB, BRNS, ORMP, INCR, MCRB, and ANVS
Should you be buying PDS Biotechnology stock or one of its competitors? The main competitors of PDS Biotechnology include Emergent BioSolutions (EBS), IO Biotech (IOBT), Cartesian Therapeutics (RNAC), Anixa Biosciences (ANIX), Cellectar Biosciences (CLRB), Barinthus Biotherapeutics (BRNS), Oramed Pharmaceuticals (ORMP), InterCure (INCR), Seres Therapeutics (MCRB), and Annovis Bio (ANVS). These companies are all part of the "pharmaceutical preparations" industry.
Emergent BioSolutions (NYSE:EBS) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, community ranking and media sentiment.
PDS Biotechnology has lower revenue, but higher earnings than Emergent BioSolutions. PDS Biotechnology is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.
PDS Biotechnology has a net margin of 0.00% compared to PDS Biotechnology's net margin of -72.11%. PDS Biotechnology's return on equity of -37.35% beat Emergent BioSolutions' return on equity.
Emergent BioSolutions received 355 more outperform votes than PDS Biotechnology when rated by MarketBeat users. Likewise, 66.45% of users gave Emergent BioSolutions an outperform vote while only 66.28% of users gave PDS Biotechnology an outperform vote.
Emergent BioSolutions currently has a consensus target price of $5.00, indicating a potential upside of 153.81%. PDS Biotechnology has a consensus target price of $17.33, indicating a potential upside of 431.70%. Given Emergent BioSolutions' stronger consensus rating and higher probable upside, analysts clearly believe PDS Biotechnology is more favorable than Emergent BioSolutions.
78.4% of Emergent BioSolutions shares are owned by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are owned by institutional investors. 1.2% of Emergent BioSolutions shares are owned by company insiders. Comparatively, 10.0% of PDS Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, Emergent BioSolutions had 1 more articles in the media than PDS Biotechnology. MarketBeat recorded 4 mentions for Emergent BioSolutions and 3 mentions for PDS Biotechnology. PDS Biotechnology's average media sentiment score of 0.20 beat Emergent BioSolutions' score of -0.19 indicating that Emergent BioSolutions is being referred to more favorably in the media.
Emergent BioSolutions has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Comparatively, PDS Biotechnology has a beta of 1.67, meaning that its stock price is 67% more volatile than the S&P 500.
Summary
Emergent BioSolutions beats PDS Biotechnology on 9 of the 17 factors compared between the two stocks.
Get PDS Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for PDSB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PDSB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PDS Biotechnology Competitors List
Related Companies and Tools
